《大行報告》美銀證券上調潤啤(00291.HK)目標價至79.8元 評級「買入」
美銀證券發表報告指,分別上調華潤啤酒(00291.HK)2023及2024財年的每股盈測6%,並升目標價6%,由75元上調至79.8元,認為集團的業績穩固,而且指引樂觀。該行指,上調對其每股盈測反映了潤啤在啤酒業務的實力,同時亦考慮了白酒的收購。該行預計2022至25財年的每股盈利複合年增長率為20%到25%,而今年應該會高於趨勢水平。疫情作為壓力測試,證明了集團的執行能力和有利的供應方行業動態。
該行表示,中國重新開放後,集團計劃利用加速的高端化進程和持續的份額增長,其白酒企業可能會提供了長期的可選性作為第二個增長動力。該行維持對潤啤「買入」評級,仍然是首選消費品牌之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.